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Background: Ovarian cancer is one of the most lethal gynecological malignancies 
and the fifth leading cause of cancer deaths among women. The high mortality rate is 
largely attributed to its diagnosis in advanced stages. Poor prognosis of ovarian cancer 
is usually due to the lack of specific or effective screening and diagnostic methods for 
identifying early-stage disease.
aim: Our study aimed to study the role of HLA-DP, HLA-DQ, and ICAM-1 SNPs in 
diagnosis and/or prognosis of ovarian tumors
subjects and methods: The current study was conducted on 60 patients with ovarian  
tumors (benign, borderline, and malignant) and 20 healthy volunteers. Genotyping 
of HLA-DP rs3077, HLA-DQ rs3920, and ICAM-1 rs1437 SNPs was done using 
5′  nuclease assay.
results: We found significant association of HLA-DP rs3077 AA, HLA-DQ rs3920 GG, 
ICAM-1 rs1437 CC, and CT genotypes with increased risk of ovarian cancer (OR = 43.5, 
6, 25, and 2.6, respectively). In addition, HLA-DQ rs3920 and ICAM-1 rs1437 alleles vary 
significantly among different types of ovarian cancer (P = 0.003 and 0.001, respectively).
conclusion: HLA-DP rs3077, HLA-DQ rs3920, and ICAM-1 rs1437 SNPs could help in 
the diagnosis and prognosis of ovarian cancer.
Keywords: ovarian cancer, hla-DP, hla-DQ, snP, icaM-1
BacKgrOUnD
Ovarian cancer is considered the most lethal gynecological malignancies and the fifth leading 
cause of cancer deaths among women, according to the National Cancer Institute’s (NCI) 2014 
statistics (1, 2). Majority of the cases are diagnosed in the late stages of the disease, resulting in 
poor survival (3). The 5-year survival rate of patients with ovarian cancer is only around 30% in 
Stage III or IV (4). This high mortality rate is attributed to the fact that ovarian cancer develops 
without obvious symptoms resulting in advanced and widespread disease when patients are first 
diagnosed (5).
Ovarian cancer has three main types; epithelial ovarian cancer (EOC), stromal tumors, and germ 
cell tumors. EOC represents about 90% of ovarian cancers and is classified into serous, mucinous, 
endometrioid, clear cell, and transitional cell tumors (2). Globally, EOC is the leading cause of 
mortality among gynecological malignancies. Therefore, developing novel predictive biomarkers 
for recurrence and metastasis is urgently needed to improve the survival of patients with EOC (6).
TaBle 1 | correlation between fluorescence signals and allele present in 
a sample.
a substantial increase in… indicates…
VIC-dye fluorescence only Homozygous for allele 1
FAM-dye fluorescence only Homozygous for allele 2
Both VIC- and FAM-dye fluorescence Allele 1–allele-2 heterozygous
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Several independent prognostic factors including age, perfor-
mance status, FIGO stage, grade of tumor, and volume of residual 
tumor have been established in predicting survival in ovarian 
cancer patients. However, these macro factors are insufficient 
to predict the outcomes. Hence, it is necessary to identify new 
prognostic molecular factors to predict the outcomes of patients 
and select the suitable treatment options for ovarian cancer 
patients (7).
During the past few years, accumulating evidences sup-
port the hypothesis that molecular events may be responsible 
for tumor initiation, metastasis, recurrence, and resistance to 
treatment.
Human leukocyte antigens (HLAs) are very important in 
tumor surveillance, since they can modulate the efficacy of cyto-
toxic T-lymphocytes through the presentation of tumor antigens. 
In some ovarian cancers, tumor-infiltrating lymphocytes (TILs) 
have been identified, indicating a local immune response and 
better prognosis. It is believed that HLA-class II antigens influ-
ence the interaction between ovarian cancer cells and the host’s 
immune response, as an increase in HLA-class II molecules on 
tumor cells will augment the existence of TILs (8). But, molecular 
mechanisms responsible for altered HLA-class II phenotypes in 
ovarian tumors need further research.
Moreover, intercellular adhesion molecule-1 (ICAM-1 CD54) 
is an inducible cell-surface glycoprotein from immunoglobulin 
supergene family, which is essential for most cell–cell interactions 
in the immune response (9). It has a role in tumorigenesis and 
tumor progression, as it modulates the occurrence and prognosis 
of several types of cancers (10); however, its role in EOC remains 
unclear.
Thus, this study aimed to investigate the role of HLA-DP 
rs3077 (A/G), HLA-DQ rs3920 (A/G), and ICAM-1 rs1437 (C/T) 
SNPs in diagnosis and/or prognosis of ovarian cancer.
sUBJecTs
This study was conducted on 80 subjects; 60 patients with 
ovarian tumors from Obstetrics and Gynecology Department, 
Faculty of Medicine, Alexandria University and 20 healthy 
volunteers. Subjects were divided into four groups; group 
1 included 20 patients with benign lesions (serous cyst and 
cystadenofibroma); 7 females were at menopause, while 13 
were in pre-menopause state, group 2 included 20 patients 
with borderline ovarian cancer (15 serous and 5 mucinous); 
12 females were at menopause, while 8 were in pre-menopause 
state, group 3 included 20 patients with malignant ovarian 
cancer (6 serous, 4 mucinous, 7 endometrioid, and 3 poorly/
undifferentiated); 10 females were at menopause, while 10 
were in pre-menopause state, and group 4 (control group) age-
matched healthy females; 4 were at menopause, while 16 were 
in pre-menopause state.
All participants were asked to freely volunteer to the study, 
and informed written consents were gathered prior to their 
inclusion in the study protocol, according to ethical guidelines 
of the Medical Research Institute, Alexandria University 
(Informed Written Consent for Patient Participation in a 
Clinical Research, 2011).
MaTerials anD MeThODs
All reagents used in the study were supplied by Applied Biosystems, 
Life Technology Company (St. Louis, MO, USA).
Assessments of HLA-DP rs3077 (A/G), HLA-DQ rs3920 
(A/G), and ICAM-1 rs1437 (C/T) SNPs were performed fol-
lowing the instructions in TaqMan® SNP Genotyping Assays 
Protocol provided by Applied Biosystems, Life Technology 
Company. Genomic DNA was extracted from whole blood sam-
ples in EDTA vacutainers using the PureLink® Genomic DNA 
Kits # K1820-01 (Invitrogen, Life Technologies) followed by 
assessment of DNA concentration and purity using a Nanodrop 
spectrophotometer. The extracted DNA was stored at −80°C till 
used.
HLA-DP rs3077 (A/G), HLA-DQ rs3920 (A/G), and ICAM-1 
rs1437 (C/T) polymorphisms were analyzed using 5′ nuclease 
assay with a TaqMan MGB (minor groove binder) probe in a 
StepOne™ Real-Time PCR System (Applied Biosystems, Life 
Technologies). SNP Genotyping Assays contain VIC® dye-
labeled probe, FAM™ dye-labeled probe, and two target-specific 
primers. TaqMan® probes incorporate MGB technology at the 
3′-end to deliver superior allelic discrimination. All MGB probes 
also include a non-fluorescent quencher (NFQ) that virtually 
eliminates the background fluorescence and provides excellent 
signal-to-noise ratio for superior assay sensitivity.
HLA-DP rs3077, HLA-DQ rs3920, and ICAM-1 rs1437 
primers and TaqMan MGB probes were provided by the assay on-
demand™ service by Applied Biosystems, Life Technologies. 2 μl 
genomic DNA, 7 μl DNase-free water, 10 μl TaqMan Universal 
PCR Master Mix (2×), and 1 μl working stock of SNP genotyp-
ing assay (20×) were added in PCR tubes. The assay contain 
sequence-specific forward and reverse primers to amplify the 
polymorphic sequence of interest and two TaqMan® MGB probes 
with NFQ (one VIC®-labeled probe to detect Allele 1 sequence 
and one FAM™-labeled probe to detect Allele 2 sequence). 
Negative controls (without DNA samples) were included in each 
run. Thermal cycling conditions were adjusted to be 10 min at 
95°C, followed by 40 PCR cycles each consisting of 15 s at 92°C 
and 1 min at 60°C. Each reaction plate was loaded into StepOne™ 
Real-Time PCR System, and then the run started.
When probes hybridized to the complementary sequence 
are cleaved, an increase in fluorescence signal occurs. Thus, the 
fluorescence signal generated by PCR amplification indicates 
which alleles are present in the sample (Table 1; Figure 1). In our 
study, VIC® dye is associated with the A allele of HLA-DP rs3077, 
A allele of HLA-DQ rs3920, and C allele of ICAM-1 rs1437, while 
FAM™ dye is associated with the G allele of HLA-DP rs3077, 
G allele of HLA-DQ rs3920, and T allele of ICAM-1 rs1437.
FigUre 1 | real-time Pcr pictures displaying (a) expression of hla-DP rs3077gg, hla-DQ rs3920 gg, or icaM-1 rs1437 TT, (B) expression of 
hla-DP rs3077aa, hla-DQ rs3920 aa, or icaM-1 rs1437 cc, and (c) heterozygous expression of both alleles “hla-DP rs3077ag, hla-DQ rs3920 
ag, or icaM-1 rs1437 cT.”
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statistical analysis of the Data
Data were analyzed using IBM SPSS software package ver-
sion 20.0. Qualitative data were described using number and 
percentage. Comparison between different groups regarding 
categorical variables was tested using Chi-square test. When 
more than 20% of the cells have expected count less than five, 
correction for Chi-square was conducted using Monte Carlo 
correction. Significance of the obtained results was judged at 
the 5% level (11).
resUlTs
subject’s Demographic Data
Age distributions among benign, borderline, and malignant ovar-
ian tumors and healthy control group did not show any statistically 
significant differences. While regarding menstrual state, there 
were statistically significant differences between borderline and 
malignant patients with the other groups (Table 2).
hla-DP rs3077 Variants among the 
studied groups
HLA-DP rs3077 AA genotype was expressed in 90, 100, 100, and 
40% of benign, borderline, malignant ovarian tumors, and healthy 
volunteers, respectively, while AG genotype was expressed in 10, 
0, 0, and 60% of benign, borderline, malignant ovarian tumors, 
and healthy volunteers, respectively. There were no any statisti-
cally significant differences among the studied groups (P = 0.126) 
(Table 3).
When comparing between patients having ovarian tumors and 
control group, we found that HLA-DP rs3077 AA genotype was 
FigUre 2 | Distribution of the studied alleles in ovarian tumors’ 
patients and healthy controls.
TaBle 4 | Distribution of the studied alleles in ovarian cancer patients 
and healthy controls.
gene group Or (95% ci)
cases controls
no % no %
hla-DP rs3077
•	 AA 58 96.7 8 40.0 43.5 (8.2–57.3)*
•	 AG 2 3.3 12 60.0 1
hla-DQ rs3920
•	 AG 20 33.3 15 75.0 1
•	 GG 40 66.7 5 25.0 6.0 (1.9–18.8)*
icaM-1 rs1437
•	 CC 16 26.7 0 0.0 25.0 (1.4–125.6)*
•	 CT 28 46.7 8 40.0 2.6 (1.0–7.8)*
•	 TT 16 26.7 12 60.0 1
OR, odds ratio; CI, confidence interval.
*Significant (P < 0.05).TaBle 3 | Distribution of hla-DP-rs3077, hla-DQ-rs3920, and icaM-1 
rs1437 alleles in the studied groups.
gene group MCP
Benign Borderline Malignant controls
no % no % no % no %
hla-DP rs3077
•	 AA 18 90.0 20 100.0 20 100.0 8 40.0 0.126
•	 AG 2 10.0 0 0.0 0 0.0 12 60.0
hla-DQ rs3920
•	 AG 2 10.0 12 60.0 6 30.0 15 75.0 0.003*
•	 GG 18 90.0 8 40.0 14 70.0 5 25.0
icaM-1 rs1437
•	 CC 2 10.0 0 0.0 14 70.0 0 0.0 0.001*
•	 CT 7 35.0 16 80.0 5 25.0 8 40.0
•	 TT 11 55.0 4 20.0 1 5.0 12 60.0
MCP, Mont Carlo exact probability.
*P < 0.05 (significant).
TaBle 5 | relation between menstrual status and the studied alleles.
Menstrual 
status
genotype group McP
cases controls
no % no %
Pre-menopause HLA-DP AA 29 93.5 4 25.0 0.001*
AG 2 6.5 12 75.0
HLA-DQ AG 7 22.6 11 68.8 0.002*
GG 24 77.4 5 31.3
ICAM1 CC 8 25.8 0 0.0 0.067
CT 11 35.5 6 37.5
TT 12 38.7 10 62.5
Menopause HLA-DP AA 29 100.0 4 100.0 –
AG 0 0.0 0 0.0
HLA-DQ AG 13 44.8 4 100.0 0.038*
GG 16 55.2 0 0.0
ICAM1 CC 8 27.6 0 0.0 0.159
CT 17 58.6 2 50.0
TT 4 13.8 2 50.0
*Significant (P < 0.05).
TaBle 2 | Distribution of age and menstrual state in the studied groups.
characteristics group MCP
Benign Borderline Malignant control
no % no % no % no %
age (years)
•	 <40 4 20.0 4 20.0 3 15.0 9 45.0 0.06
•	 40–50 6 30.0 4 20.0 3 15.0 5 25.0
•	 50–60 6 30.0 8 40.0 6 30.0 4 20.0
•	 60–70 4 20.0 4 20.0 8 40.0 2 10.0
Menstrual status
•	 Pre-menopause 13 65.0 8 40.0 10 50.0 16 80.0 0.047*
•	 Menopause 7 35.0 12 60.0 10 50.0 4 20.0
MCP, Mont Carlo exact probability.
*P < 0.05 (significant).
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expressed in 96.7 and 40% of ovarian tumors patients and healthy 
volunteers, respectively, while AG genotype was expressed in 
3.3 and 60% of ovarian tumors patients and healthy volunteers, 
respectively. There was statistically significant association 
between HLA-DP rs3077 AA genotype and the occurrence of 
ovarian cancer, as AA allele has 43.5-folds more odds to be cases 
compared to AG allele. So, HLA-DP rs3077 AA is a good predic-
tor for ovarian cancer (OR = 43.5, 95% CI = 8.2–57.3) (Table 4; 
Figure 2). Correlation analysis clarified that HLA-DP rs3077 AA 
is highly expressed in all ovarian cancer females regardless the 
menstrual state (Table 5).
hla-DQ rs3920 Variants among the 
studied groups
HLA-DQ rs3920 AG genotype was expressed in 10, 60, 30, 
and 75% of benign, borderline, malignant ovarian tumors, 
and healthy volunteers, respectively, while GG genotype was 
expressed in 90, 40, 70, and 25% of benign, borderline, malignant 
ovarian tumors, and healthy volunteers, respectively. There were 
statistically significant differences among the studied groups 
5Ghazy and El-Etreby Relevance of SNP in Ovarian Cancer
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(P = 0.003), so HLA-DQ rs3920 alleles could be good predictors 
for type of ovarian tumor (Table 3).
When comparing between patients having ovarian tumors and 
control group, we found that HLA-DQ rs3920 AG genotype was 
expressed in 33.3 and 75% of ovarian tumors patients and healthy 
volunteers, respectively, while GG genotype was expressed in 
40 and 25% of ovarian tumors patients and healthy volunteers, 
respectively. There was statistically significant relation between 
HLA-DQ rs3920 GG genotype and risk of ovarian cancer, as 
HLA-DQ rs3920 GG allele has sixfolds more odds to be cases 
compared to AG allele. So, HLA-DQ rs3920 GG is a good predic-
tor for ovarian cancer (OR =  6, 95% CI =  1.9–18.8) (Table  4; 
Figure 2). Correlation analysis clarified that HLA-DQ rs3920 GG 
is highly expressed in all ovarian cancer females regardless the 
menstrual state (Table 5).
icaM-1 rs1437 Variants among the 
studied groups
ICAM-1 rs1437 CC genotype was expressed in 10, 0, 70, and 0% 
of benign, borderline, malignant ovarian tumors, and healthy 
volunteers, respectively, while CT genotype was expressed in 35, 
80, 25, and 40% of benign, borderline, malignant ovarian tumors, 
and healthy volunteers, respectively. There were statistically 
significant differences among the studied groups (P = 0.001), so 
ICAM-1 rs1437 SNP could be a good predictor for progression of 
ovarian tumor (Table 3).
When comparing between patients having ovarian tumors 
and control group, we found that ICAM-1 rs1437 CC, CT, and 
TT genotypes were expressed in 26.7, 46.7, and 26.7% of ovarian 
tumors patients, respectively, while for healthy volunteers; CC, 
CT, and TT genotypes were expressed in 0, 40, and 60% of healthy 
volunteers, respectively, There was statistically significant associa-
tion between ICAM-1 rs1437 CC and CT genotypes and ovarian 
cancer, as they have 25- and 2.6-folds, respectively, more odds to 
be ovarian cancer cases compared to TT allele. So ICAM-1 rs1437 
CC and CT genotypes are good predictors for ovarian cancer; 
particularly CC allele (Table 4; Figure 2).
DiscUssiOn
Ovarian cancer ranks among the top 10 diagnosed cancers 
and top 5 deadliest cancers in most countries (12). Prognosis 
of ovarian cancer is usually poor, due to the lack of effective 
screening and diagnostic methods to identify early-stage disease 
(7). Unfortunately, the molecular mechanisms of ovarian cancer 
remain unclear, and the attempts to develop effective methods 
that help in early detection and monitoring of tumor progression 
have great potential to improve patients’ survival. Thus in our 
samples, we have analyzed HLA-DP rs3077 (A/G), HLA-DQ 
rs3920 (A/G), and ICAM-1 rs281437 (C/T) SNPs in benign, 
borderline, malignant ovarian tumors’ patients, and normal 
controls.
We found that HLA-DP rs3077 AA and HLA-DQ rs3920 GG 
alleles are significantly associated with ovarian cancer incidence 
(OR = 43.5 and 6, respectively). Thus, they could help in early 
diagnosis of that disease. This can be explained by the fact that 
HLA-II presents tumor antigens to immune cells that are respon-
sible for their clearance. Additionally, distribution of HLA-DQ 
rs3920 alleles varies greatly among different types of ovarian 
cancer (P = 0.003).
Expression of HLA-DP rs3077 A and/or HLA-DQ rs3920 
G increases with the increase in tumor aggressiveness, as their 
expression was mild in control, moderate among benign, and 
high in borderline and malignant groups. This aberrant expres-
sion may have a role in tumor progression, advanced stages of 
tumor, and bad prognosis of patients.
These results were in agreement with Kübler et  al. (8, 13), 
who have documented that MHC complex has a central role 
within the immunological integrity of the ovary, and the aber-
rant expression of HLA-class I and II molecules are supposed 
to contribute to cancer susceptibility or resistance to treatment. 
They recommended further investigations about the involvement 
of HLA-class II genes in the pathogenesis of this disease. Jiang 
et al. (14) have focused on the role of HLA in cervical cancer risk, 
and they found consistently significant associations of HLA-DP 
rs3077 with increased risks of cervical cancer (OR = 1.51, 95% 
CI =  1.32–1.71) and proposed it as susceptibility marker for 
cervical cancer among Chinese females. So, further validation 
studies on larger sample size are needed in our population.
Additionally, abnormal expression of adhesion molecules, 
as ICAM-1, has an integral role in tumor growth, invasion, 
metastasis, and evasion from the host immune defense (9). This 
agree with our results, where there was statistically significant 
association between ICAM-1 rs1437 CC and CT genotypes 
and ovarian cancer (OR =  25 and 2.6, respectively), so they 
are good predictors for ovarian cancer risk; particularly CC 
allele. Furthermore, ICAM-1 rs1437 alleles vary significantly 
among the different types of ovarian cancer where T allele is 
expressed more among benign cases, while C allele expression 
increases in the aggressive types (P = 0.001). So, they could help 
in predicting the disease progression and prognosis of ovarian 
cancer patients.
Cai et al. (10) have evaluated SNPs in ICAM-1 as predictors 
of EOC risk and prognosis. They found that ICAM-1 rs5498 G 
allele is associated with increased tumor grade (OR =  2.650) 
and risk (OR =  1.405). This risk was more evident in females 
who had first-degree relatives with a tumor (OR = 3.475) or who 
experienced early menarche (OR = 2.774). They concluded that 
ICAM-1 rs5498 likely confers a high risk for EOC in G allele car-
riers accompanied by upregulation of ICAM-1 expression during 
carcinogenesis. The combination of ICAM-1 rs5498 and tumor 
history predicts the EOC prognosis.
Indeed, HLA-class II and/or ICAM-1 SNP may influence the 
tumor-specific mechanisms, as the statistical analysis showed 
strong association between certain alleles and ovarian cancer; 
particularly aggressive types.
cOnclUsiOn
The results of the present study provides a clue on the relevance of 
HLA-DP rs3077, HLA-DQ rs3920, and ICAM-1 rs1437 variants 
in ovarian cancer, as some alleles were identified to be linked with 
ovarian cancer as HLA-DP rs3077 AA, HLA-DQ rs3920 GG, 
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ICAM-1 rs1437 CC, and CT genotypes (OR = 43.5, 6, 25, and 2.6, 
respectively). These alleles confer a high risk for EOC among their 
carriers’ especially first-degree relatives of patients. Additionally, 
we found that HLA-DQ rs3920 and ICAM-1 rs1437 alleles vary 
among different groups of ovarian cancer and are good predictors 
for tumor type (P =  0.003 and 0.001, respectively). They could 
help in predicting prognosis of ovarian cancer patients. The main 
limitation in our study is the small sample size. So, further research 
on a larger patient sample is recommended to confirm the positive 
correlation between ovarian cancer and these variants.
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